Protagonist Therapeutics (PTGX) Getting Somewhat Favorable Media Coverage, Report Shows

Press coverage about Protagonist Therapeutics (NASDAQ:PTGX) has been trending somewhat positive this week, according to Accern Sentiment. The research firm scores the sentiment of press coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Protagonist Therapeutics earned a media sentiment score of 0.17 on Accern’s scale. Accern also gave news stories about the company an impact score of 46.605284480026 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.

Several analysts recently issued reports on the stock. ValuEngine lowered shares of Protagonist Therapeutics from a “hold” rating to a “sell” rating in a report on Monday. Zacks Investment Research upgraded shares of Protagonist Therapeutics from a “hold” rating to a “buy” rating and set a $14.00 price objective on the stock in a report on Friday, August 18th. BTIG Research assumed coverage on shares of Protagonist Therapeutics in a report on Friday, July 21st. They issued a “buy” rating and a $36.00 price objective on the stock. Finally, BMO Capital Markets boosted their price objective on shares of Protagonist Therapeutics from $34.00 to $45.00 and gave the company an “outperform” rating in a report on Wednesday, May 31st.

Shares of Protagonist Therapeutics (NASDAQ PTGX) opened at 14.42 on Wednesday. The company has a 50-day moving average of $13.25 and a 200 day moving average of $12.07. Protagonist Therapeutics has a one year low of $8.00 and a one year high of $26.36. The stock’s market capitalization is $243.73 million.

Protagonist Therapeutics (NASDAQ:PTGX) last released its earnings results on Tuesday, August 8th. The company reported ($0.89) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.19) by ($0.70).

In other news, insider David Y. Liu sold 3,500 shares of the stock in a transaction dated Monday, August 28th. The stock was sold at an average price of $15.00, for a total value of $52,500.00. Following the completion of the sale, the insider now owns 5,500 shares in the company, valued at $82,500. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Richard S. Shames sold 1,512 shares of the stock in a transaction dated Tuesday, August 29th. The shares were sold at an average price of $17.00, for a total value of $25,704.00. The disclosure for this sale can be found here. Insiders have sold 12,199 shares of company stock worth $175,345 over the last quarter.

ILLEGAL ACTIVITY WARNING: This news story was originally published by Stock Observer and is owned by of Stock Observer. If you are accessing this news story on another website, it was copied illegally and republished in violation of US and international copyright and trademark legislation. The correct version of this news story can be viewed at https://www.thestockobserver.com/2017/09/13/protagonist-therapeutics-ptgx-getting-somewhat-favorable-media-coverage-report-shows.html.

Protagonist Therapeutics Company Profile

Protagonist Therapeutics, Inc is a clinical-stage biopharmaceutical company with a peptide technology platform focused on discovering and developing new chemical entities (NECs) to address significant unmet medical needs. The Company’s product pipeline includes PTG-100, PTG-200 and PTG-300. Its primary focus is on developing oral peptide drugs that target biological pathways also targeted by marketed injectable antibody drugs.

Insider Buying and Selling by Quarter for Protagonist Therapeutics (NASDAQ:PTGX)

Receive News & Ratings for Protagonist Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagonist Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply